miR-628 reduces prostate cancer proliferation and invasion via the FGFR2 signaling pathway

JUN CHEN, PENG HAO, TAO ZHENG and YONG ZHANG

Department of Urology, Wuhan Fourth Hospital, Puai Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan 430033, P.R. China

Received July 7, 2018; Accepted January 31, 2019

DOI: 10.3892/etm.2019.7682

Abstract. Recently, microRNA (miR)-628 was identified as a potential biomarker for several types of cancer, including prostate cancer (PCa). The aim of the present study was to investigate miR-628 expression and its underlying mechanism in PCa cell proliferation and invasion and the fibroblast growth factor receptor 2 (FGFR2) signaling pathway. The serum expression levels of miR-628, prostate-specific antigen, fibroblast growth factor 1, and FGFR2 were examined in patients with PCa. The relative expression levels of miR-628 and FGFR2 were determined by reverse transcription-quantitative polymerase chain reaction in PCa cells following transfection with miR-628-5p mimic or inhibitor. In addition, the protein expression level of FGFR2 was examined by western blot analysis following transfection with miR-628-5p mimic or inhibitor. Following bioinformatics analysis, dual-luciferase reporter assay was used to confirm the direct interaction between miR-628 and FGFR2. The current study demonstrated that the protein expression level of FGFR2 decreased following transfection with miR-628-5p mimic and increased following transfection with miR-628-5p inhibitor. Similarly, the proliferation and invasion of PCa cells were significantly enhanced following transfection with miR-628-5p inhibitor. By contrast, the proliferation and invasion of PCa cells were significantly inhibited following transfection with miR-628 mimic. Therefore, downregulating the expression level of miR-628 may increase the expression level of FGF in PCa, thereby promoting tumor proliferation and invasion. In conclusion, the FGF signaling pathway may be involved in promoting PCa cell proliferation and invasion. miR-628 may be a potential therapeutic target for patients with PCa.

Introduction

Prostate cancer (PCa) is the most common malignancy and the leading cause of cancer mortality among men in the USA and Europe (1,2). The male population with a median age >60 years is more susceptible to PCa (3,4). In total, there are >1 million newly diagnosed cases of PCa identified each year and ~300,000 cases succumb to the disease (5). The incidence and mortality rates of PCa vary due to genetic variation and environmental changes between different age and ethnic groups (3,5-7). Exercise, obesity, smoking, vitamins, micronutrients, metformin, statins and other medications are all considered to be critical factors, which can affect the incidence and mortality rates of PCa (5,6). In addition, the incidence rate increases significantly in urban areas of China, South Korea and other countries (1,3,6).

Testosterone serves a key role in the development, growth and maintenance of the prostate (8,9) and abnormal prostate cell proliferation and differentiation caused by hormonal regulation may be involved in the initiation of hypertrophy, hyperplasia and malignancy (8,9). Many growth factors, including epidermal growth factor, fibroblast growth factor (FGF), insulin-like growth factor, transforming growth factor β1 and keratinocyte growth factor are also involved (8,10). FGFs can activate FGF receptors (FGFRs), which can lead to wound repair and neovascularization, as well as tumor growth and differentiation, thereby making FGF a potential therapeutic target in the development of novel anti-cancer treatments (11,12).

Early diagnosis of PCa is key to reducing morbidity and mortality (8). The main treatment options for early-stage PCa involve monitoring the prostate, whereas late-stage PCa requires radiation, surgery and other treatments, such as systemic chemotherapies or targeted therapies (8). Radical prostatectomy followed by radiotherapy in combination with hormonal treatment is widely used to treat patients with recurrent PCa (8,13). Furthermore, treatment outcome varies dramatically as clinical heterogeneity is another feature associated with PCa (8,13).

microRNAs (miRNAs or miRs) are single-stranded small RNAs, 18-23 nucleotides in length which can regulate gene expression through mRNA degradation or protein synthesis inhibition (14,15). miRNAs can regulate several physiological or pathological processes including cell proliferation,
differentiation, stress and death (14,15), miRNAs have been identified in several types of cancer and can function as positive or negative regulators, depending on their target gene (16,17). miR-628, which is located at 15q21.3, was initially identified in acute myeloid leukemia and is regulated by interleukin-3, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor (15). A previous study demonstrated that miR-628 is an endotoxin-responsive gene induced by lipopolysaccharide as well as a nuclear factor κB-dependent gene (18). miR-628 can regulate inflammatory responses by targeting a key adapter molecule downstream of toll-like receptors (TLRs) to suppress TLR signaling (18).

In addition, miR-628 mediates burn-induced skeletal muscle atrophy through regulation of the insulin receptor substrate 1/protein kinase B serine/threonine kinase 1/forkhead box protein O 3a signaling pathway (19). miR-628-3p is upregulated in patients with bone fractures and miR-628-3p can exert an inhibitory effect on osteogenesis via the suppression of runt related transcription factor 2 leading to atrophic non-union, a complication associated with bone fractures (20). Furthermore, miR-628-3p is involved in rifampin-mediated cytochrome P450 family 3 subfamily A member 4 (CYP3A4) induction as it is thought to directly target CYP3A4 (21). miR-628-5p has previously been demonstrated to decrease the stem-like cell percentage of epithelial ovarian cancer (EOC) cells by inducing their apoptosis as well as decreasing the tumorigenicity of EOC cells by targeting FGFR2 (11).

A previous study identified miR-628 as a potential non-invasive biomarker for PCa (14), however whether miR-628 serves a tumor suppressing role in PCa remains unknown. In addition, whether FGFR2 is a direct target of miR-628 in PCa remains unknown. Therefore, the aim of the present study was to investigate miR-628 expression and its underlying mechanism in PCa cell proliferation and invasion and the FGFR2 signaling pathway.

Materials and methods

PCa and healthy control patients. A total of 33 patients with PCa (males; age range, 55-89 years; average age, 70 years) were recruited in Wuhan Fourth Hospital, Puai Hospital (Wuhan, China) between January 2016 and December 2017 for inclusion in the current study. Patients were diagnosed following prostate biopsy or postoperative pathological examination. Patients with PCa with a Gleason score range from 4-10 were included in the study. In total, 12 patients had a Gleason score of 4-6 (well differentiated), 9 patients had a Gleason score of 7 (medium differentiated) and 12 patients had a Gleason score of 8-10 (low differentiated). A summary of the cancer staging and Gleason score for patients with PCa is presented in Table I. In addition, 26 healthy control patients (age range, 62-82 years; average age, 79 years) were recruited following admittance to the hospital physical examination center of Wuhan Fourth Hospital, Puai Hospital (Wuhan, China) for a health check-up between January 2016 and December 2017. Blood pressure, urine routine test, and liver and kidney function were all within the normal range. Patients with other diseases affecting heart, lungs or other vital organs, such as benign prostatic hyperplasia and other prostate-associated diseases were excluded. The current study was approved by the Ethics Committee of Wuhan Fourth Hospital, Puai Hospital (Wuhan, China) and written informed consent was obtained from all participants.

Specimen collection. Venous blood samples (4 ml) were collected from all participants (PCa and control) in the fasting state prior to any treatment, which included medication, hormonal treatment, surgery, as well as rectal examination, prostate massage and puncture within 1 week before blood extraction. Blood was centrifuged at 1,200 x g at room temperature for 12 min to collect serum. Serum prostate-specific antigen was measured immediately using an ADVID Centaur CP analyzer (Siemens Healthineers, Erlangen, Germany). The remaining serum was stored at -20°C and used to determine serum expression levels of miR-628, FGF-1 and FGFR2 using an IMMULITE®1000 immunoassay system (Siemens Healthineers).

Cell culture. Human prostate adenocarcinoma cell line LNCaP (ATCC® CRL-1740™) was purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (ATCC) supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 mg/ml streptomycin, and maintained at 37°C in an atmosphere containing 5% CO₂.

Cell transfection. MiR-628-5p mimic (5’-AUGCUGACA UAUUUAUCAGGG-3’; cat. no. MCH03275) and negative control miRNA (cat. no. MCH00000), as well as miR-628-5p inhibitor (cat. no. MIH03275) or negative control inhibitor (cat. no. MIH00000) was purchased from Applied Biological Materials Inc., (Richmond, BC, Canada). Lipofectamine 2000 (Thermo Fisher Scientific, Inc.) was used to transfect 35 nM miR-628-5p mimic and negative control miRNA (negative control), as well as 35 nM miR-628-5p inhibitor or negative control inhibitor (negative control) into 10⁶ cells. Untransfected cells were considered control cells. Subsequent experiments were performed at 24 h post-transfection.

MTT cytotoxicity assays. LNCaP cells were seeded into 96-well plates (3x10⁴ cells in 0.1 ml culture medium per well) and transfected with miR-628-5p mimic (cat. no. MCH03275), miR-628-5p inhibitor (cat. no. MIH03275; both Applied Biological Materials Inc., Richmond, BC, Canada) or control. Following 12-h incubation, 10 µl MTT solution (5 mg/ml) was added and cells were incubated for a further 2 h at 37°C. Following incubation, cell culture medium was removed and dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was added to dissolve the purple formazan crystals. Optical density was measured at 570 nm using a luminometer microplate reader (Berthold Technologies GmbH, Bad Wildbad, Germany).

Cell invasion assay. Transwell inserts (8 µm) were used. Upper chambers were pre-coated with 40 ml Matrigel® (BD Biosciences, Franklin Lakes, NJ, CA, USA) dissolved in 20% culture medium and incubated overnight at 37°C. In total, 5x10⁵ cells collected at 24 h after transfection were suspended in 200 ml serum-free RPMI-1640 medium and were plated in the upper chamber. RPMI-1640 medium supplemented with
ELISA. Prostate-specific antigen (PSA), fibroblast growth factor (FGF1) and FGFR2 in plasma were detected by performing ELISA using human Prostate Specific Antigen ELISA Kit (cat. no. ab188388; Abcam), Human FGF1 ELISA Kit (cat. no. ab219636; Abcam) and FGFR2 ELISA kit (cat. no. MBS921985; MyBioSource; Thermo Fisher Scientific, Inc.) respectively.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from LNCaP cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA (≤500 ng) was reverse transcribed into cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). To examine the mRNA expression level of FGFR2, qPCR was performed using the SYBR™ Green Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) to examine the expression level of miR-628, qPCR was performed using the TaqMan probe kit (Roche Applied Science, Penzberg, Germany). qPCR was performed using an ABI 7900 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following primer pairs were used for qPCR: FGFR2 forward, 5'-CGC TGGTGGAGATAACACAGC-3' and reverse, 5'-TGGAAG TTCATACGGAGAACC-3'; GAPDH forward, 5'-GTCTCC TCTGACTTCAA-3' and reverse, 5'-ACCACCCCTTGCGTG TA-3'; miR-628 forward primer: 5'-GTCGTATACGACGT TTATATCC-3'; miR-628 reverse primer and U6 primers were included in the kit. The thermocycling conditions for qPCR were: Initial denaturation at 95°C for 10 sec; 40 cycles of 95°C for 10 sec and 60°C for 60 sec. FGFR2 and miR-628 expression was quantified using the $2^{-\Delta\Delta CT}$ method (15) and normalized to the internal reference gene GAPDH or U6 small non-coding RNA, respectively.

Western blot analysis. Total protein was extracted from LNCaP cells using the M-Per™ Mammalian Protein Extraction reagent (Pierce; Thermo Fisher Scientific, Inc.). Protein concentration was determined by BCA assay. An equal volume of protein was mixed with an equal volume of 2X SDS loading buffer and boiled for 5 min. Proteins (30 μg per lane) were separated via SDS-PAGE on a 10% gel and transferred onto polyvinylidene difluoride membranes (Zhongshan Jinqiao Biology & Technology Co., Ltd., Beijing, China). Membranes were blocked with 5% skimmed milk at room temperature for 2 h. The membranes were incubated with primary antibodies against FGFR2 (1:800; cat. no. ab58201; Abcam, Cambridge, MA, USA) and GAPDH (1:800; cat. no. sc-47724; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) overnight at 2-8°C. Following primary incubation, membranes were incubated with horseradish peroxidase-labeled goat anti-mouse immunoglobulin G secondary antibody (1:1,200; cat. no. ZB2305; Zhongshan Jinqiao Biology & Technology Co., Ltd.) at room temperature for 3 h. Protein bands were visualized using a Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences, Shanghai, China).

Dual-luciferase reporter assay. TargetScan (http://www.targetscan.org/vert_72/) and miRDB (http://mirdb.org/) bioinformatics software was used to identify the 3' untranslated region (UTR) of FGFR2 as a putative target of miR-628. The wild-type (wt) and mutant (mut) 3'UTR of FGFR2, which contains a sequence targeting miR-628, were cloned into the psi-CHECK vector (Promega Corporation, Madison, WI, USA). Cells were co-transfected with either miR-628-5p mimic (or miR-628-5p inhibitor) and psiFGFR2-wt (or psiFGFR2-mut) using Lipofectamine® 2000 (Thermo Fisher Scientific, Inc.). Control miRNA or control inhibitor were used as controls. Following 48-h transfection, cells were harvested and luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega Corporation) using a luminometer (Berthold Technologies GmbH). Firefly luciferase activity was normalized to Renilla luciferase activity.

Table I. Serum levels of PSA, FGF1 and FGFR2 in patients with PCa.

| Group   | n | PSA (ng/l) | FGF1 (pg/ml) | FGFR2 (pg/ml) |
|---------|---|------------|--------------|---------------|
| Control | 26| 1.03±0.62  | 203.72±25.27 | 64.14±11.11   |
| PCa     | 33| 21.65±12.18| 304.02±45.79 | 88.26±10.09   |
| Gleason score | | | | |
| 4-6     | 12| 13.42±5.69 | 304.93±57.13 | 88.60±12.92   |
| 7       | 9 | 20.87±12.86| 318.36±29.26 | 88.40±8.19    |
| 8-10    | 12| 30.46±10.97| 292.36±43.54 | 87.03±9.24    |
| Clinical stage | | | | |
| T1      | 4 | 8.09±1.94  | 314.42±60.76 | 89.125±12.17  |
| T2      | 6 | 15.15±5.51 | 304.03±54.08 | 86.65±14.13   |
| T3      | 15| 20.34±10.35| 308.78±43.85 | 88.19±8.56    |
| T4      | 8 | 35.76±8.27 | 289.89±41.58 | 86.49±10.86   |

PSA, prostate-specific antigen; FGF1, fibroblast growth factor 1; FGFR2, fibroblast growth factor receptor 2; PCa, prostate cancer.
miR-628 expression is decreased in the serum of patients with PCa. Serum samples from patients with PCa and healthy controls were collected and used for gene expression analyses. The expression level of miR-628 was significantly decreased in patients with PCa compared with healthy controls (Fig. 1). In addition, the expression levels of FGF1 and its receptor FGFR2 were significantly increased in patients with PCa compared with healthy controls (Fig. 2).

miR-628 expression negatively correlates with FGFR2. Serum levels of PSA were increased in patients with PCa compared with healthy controls (Table 1). Pearson correlation coefficient analysis was performed to determine the association between the serum expression level of miR-628 and FGF1 or FGFR2. The results of the current study demonstrated that there was a significant negative correlation between the serum level of miR-628 and both FGF1 and FGFR2 in patients with PCa (Fig. 3).

miR-628 regulates FGFR2 signaling. To determine the effect of miR-628 on the expression level of FGFR2, LNCaP cells were transfected with miR-628-5p mimic, inhibitor or negative controls, and miR-628 and FGFR2 expression levels were examined. The current study demonstrated that the miR-628-5p mimic significantly increased miR-628 expression (Fig. 4A), whereas the miR-628-5p mimic had no significant effect on the mRNA expression level of FGFR2 in LNCaP cells (Fig. 4B). In addition, the miR-628-5p inhibitor significantly decreased miR-628 expression (Fig. 4C), while the miR-628-5p inhibitor had no significant effect on the mRNA expression level of FGFR2 in LNCaP cells (Fig. 4D). Although there was no effect on the FGFR2 mRNA expression level, the FGFR2 protein expression level was revealed to be potentially regulated by miR-628. The protein expression level of FGFR2 decreased markedly following transfection with miR-628-5p mimic (Fig. 4E), while the protein expression level of FGFR2 increased following transfection with miR-628-5p inhibitor (Fig. 4F). Taken together, these results suggest that miR-628 can inhibit FGFR2 protein expression in PCa cell lines without affecting transcriptional levels and therefore miR-628 may regulate FGFR2 expression.

miR-628 directly targets FGFR2. TargetScan and miRDB bioinformatics software was used to identify the 3'UTR of FGFR2 as a putative target of miR-628 (Fig. 5A) and dual-luciferase reporter assays were performed to validate the direct interaction between miR-628 and FGFR2. Luciferase activity was significantly decreased following co-transfection with miR-628-5p mimic and psiFGFR2-wt compared with psiFGFR2-mut, which had no significant effect on luciferase activity (Fig. 5B). In addition, luciferase activity was significantly increased following co-transfection with miR-628-5p inhibitor and psiFGFR2-wt compared with psiFGFR2-mut, which had no effect on luciferase activity (Fig. 5C). Taken together, these results suggest that miR-628 directly interacts with FGFR2.

miR-628 regulates tumorigenesis via FGFR2 signaling pathway. The effect of miR-628 on PCa cell proliferation and invasion was examined in LNCaP cells following transfection with miR-628-5p mimic, inhibitor or negative controls. Cell proliferation and invasion was significantly increased in LNCaP cells following transfection with miR-628-5p inhibitor compared with the control group (Fig. 6A and B). By contrast, cell proliferation and invasion was significantly decreased in LNCaP cells following transfection with miR-628-5p mimic compared with the control group (Fig. 6C and D). FGF is known to promote the proliferation of tumor cells and the formation of tumor blood vessels (11) and therefore, down-regulating miR-628 expression may increase the expression level of FGF in PCa and thereby promote tumor initiation, expansion and metastasis.

Discussion

Several miRNAs, which include miR-21, miR-221 and miR-141, have been associated with PCa (20). Most of these miRNAs are involved in cell cycle, migration, metastasis, apoptosis, proliferation, angiogenesis and epithelial-to-mesenchymal transition (22). A previous study demonstrated that the serum expression level of miR-628 was significantly downregulated in African American and Caucasian American patients with PCa (14). Similarly, the current study confirmed that the serum expression level of miR-628 was significantly downregulated in Chinese patients with PCa. The FGFR2 signaling pathway is known to be involved in several types of cancer. A recent study demonstrated that miR-628 targeted and downregulated the expression of FGFR2 in ovarian cancer (11). In the current study, serum expression levels of FGF1, FGFR2 and PSA were examined in patients with PCa and controls. Serum FGF1 and
Figure 2. Expression levels of FGF1 and FGFR2 in patients with PCa. Serum expression levels of (A) FGF1 and (B) FGFR2 in patients with PCa and healthy controls. ** P<0.01 vs. control. FGF1, fibroblast growth factor 1; FGFR2, fibroblast growth factor receptor 2; PCa, prostate cancer.

Figure 3. Correlation analysis between the serum expression levels of miR-628 and FGF-1 or FGFR2 in patients with PCa. Pearson correlation coefficient analyses were performed to determine the association between the serum expression level of miR-628 and (A) FGF1 or (B) FGFR2. miR, microRNA; FGF1, fibroblast growth factor 1; FGFR2, fibroblast growth factor receptor 2; PCa, prostate cancer.

Figure 4. Effect of miR-628 on the expression level of FGFR2 in PCa cells. The relative expression level of (A) miR-628 and (B) FGFR2 was determined in the LNCaP cell line following transfection with miR-628-5p mimic. The relative expression level of (C) miR-628 and (D) FGFR2 was determined in the LNCaP cell line following transfection with miR-628-5p inhibitor. The protein expression level of FGFR2 was determined by western blot analysis in LNCaP cells following transfection with (E) miR-628-5p mimic or (F) miR-628-5p inhibitor. ** P<0.01 vs. control. miR, microRNA; FGFR2, fibroblast growth factor receptor 2; PCa, prostate cancer; LNCaP, human prostatic adenocarcinoma cell line.
FGFR2 were negatively correlated with the serum expression level of miR-628. In addition, dual-luciferase reporter assays revealed that FGFR2 is a direct target of miR-628. Furthermore, the current study demonstrated that miR-628 inhibited PCa cell proliferation and invasion via the FGFR2 signaling pathway.

The FGFR2 gene at human chromosome 10q26 encodes two isoforms, FGFR2b and FGFR2c, which function as FGFRs and are involved in tumorigenesis (23-25). Missense mutations, copy number variation, splicing and single nucleotide polymorphisms within intron 2 of the FGFR2 gene are associated with breast, bladder and gastric cancer whereby aberrant FGFR2 signaling activation induces proliferation and survival of tumor cells (23-25). FGFR2 alternative splicing serves a role in the progression of PCAs from an androgen-sensitive to androgen-insensitive tumor (26-28). Although FGFR2 inhibitors are approved and used for cancer treatment (11), the current study identified miR-628, which may be used as a potential molecular target for the development of novel therapeutic treatment strategies for patients with PCa. In addition, targeting miR-628 may also be used to treat ovarian cancer as well as inflammation regulation (15,19).

Several technologies including human antibody, peptide mimic, RNA aptamer, small interfering RNA and synthetic miRNA are emerging technologies, which can be applied and used as potential therapeutic treatment strategies in FGFR2-mediated cancer (24). In particular, these technologies may be used for the treatment of patients with PCa with low expression of miR-628 and upregulated FGFR2 signaling. Curcumin, for example, has a variety of pharmacological effects including anti-cancer effects and curcumin exerts its therapeutic effects through regulation of miRNA expression (17). miRNAs

Figure 5. FGFR2 is a direct target of miR-628. (A) TargetScan and miRDB bioinformatics software was used to predict the potential binding site for miR-628-5p binding site in the wild-type and mutant 3'UTR of FGFR2. Luciferase activity of the wt or mut 3'UTR of FGFR2 following transfection with (B) miR-628 mimic or (C) miR-628 inhibitor. *P<0.01 vs. control. miR, microRNA; FGF1, fibroblast growth factor 1; FGFR2, fibroblast growth factor receptor 2; UTR, untranslated region; wt, wild-type; mut, mutant.

Figure 6. miR-628 knockdown promotes the LNCaP cell proliferation and migration. (A) MTT assay was used to examine the cell proliferation of LNCaP cells following transfection with miR-628-5p inhibitor. (B) Cell invasion assay was analyzed via Transwell assay in LNCaP cells following transfection with miR-628-5p inhibitor. (C) MTT assay was used to examine cell proliferation of LNCaP cells following transfection with miR-628-5p mimic. (D) Cell invasion assay was analyzed via Transwell assay in LNCaP cells following transfection with miR-628-5p mimic. *P<0.01 vs. control. miR, microRNA; LNCaP, human prostatic adenocarcinoma cell line; PCa, prostate cancer.
are thought to be potential targets for cancer therapy and as such there have been a number of studies regarding miRNA regulation via miRNA activators and inhibitors (16,29-32). However, developing novel delivery systems for miRNA treatment is key to its success as a potential therapy (31).

Further experiments are required to validate the findings of the current study using in vivo mouse models, such as examining tumorigenesis in a xenograft mouse model. In vivo mouse models for PCa could be used to study miR-628 expression and regulation of the FGFR2 signaling pathway, as well as testing newly designed miR-628 activators. However, a critical step will be to develop a delivery system for the efficient delivery of miRNAs into in vivo mouse models for PCa. The current study identified the FGFR2 signaling pathway as a potential therapeutic target, however, patients may become resistant to FGFR2-mediated therapy and alternative treatment may be required. Sequencing technology may be used to develop treatments combining FGFR2 inhibition and miR-628 upregulation, which may be a potentially effective approach for the treatment of patients with PCa.

In conclusion, the present study demonstrated that miR-628 directly targets FGFR2 and miR-628 can regulate tumorigenesis via the FGFR2 signaling pathway in PCa cells. Therefore, FGFR2 and miR-628 may be potential molecular targets for the development of novel and effective therapeutic treatment strategies for patients with PCa.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

JC and YZ designed experiments. YZ and PH performed experiments. TZ analyzed data. YZ drafted this manuscript and all authors approved this manuscript.

Ethics approval and consent to participate

The current study was approved by the Ethics Committee of Wuhan Fourth Hospital, Puai Hospital (Wuhan, China). All patients and healthy volunteers provided written informed consent prior to their inclusion in the study.

Patient consent for publication

Patients provided consent for publication of data in this paper.

Competing interests

The authors declare that they have no competing interests.

References

1. Han HH, Park JW, Na JC, Chung BH, Kim CS and Ko WJ: Epidemiology of prostate cancer in South Korea. Prostate Int 3: 99-102, 2015.
2. Bashir MN: Epidemiology of prostate cancer. Asian Pac J Cancer Prev 16: 5137-5141, 2015.
3. Ye D and Y Zhu: Epidemiology of prostate cancer in China: An overview and clinical implication. Zhonghua Wai Ke Za Zhi 53: 249-252, 2015 (In Chinese).
4. Tao ZQ, Shi AM, Wang XK and Zhang WD: Epidemiology of prostate cancer: Current status. Eur Rev Med Pharmacol Sci 19: 805-812, 2015.
5. Cooperberg MR and Chan JM: Epidemiology of prostate cancer. World J Urol 35: 849, 2017.
6. Kimura T and Egawa S: Epidemiology of prostate cancer in Asian countries. Int J Urol 25: 524-531, 2018.
7. Tourinho-Barbosa RR, Pompeo AC and Glina S: Prostate cancer in Brazil and Latin America: Epidemiology and screening. Int J Urol 42: 1081-1090, 2016.
8. Beltran H, Antonarakis ES, Morris MJ and Attard G: Emerging molecular biomarkers in advanced prostate cancer: Translation to the clinic. Am Soc Clin Oncol Educ Book 35: 131-141, 2016.
9. Chen W, Wang GM, Guo JM, Sun LA and Wang H: NGFαγ-IFN inhibits androgen-independent prostate cancer and reverses androgen receptor function through downregulation of FGFR2 and decrease in cancer stem cells. Stem Cells Dev 21: 3372-3380, 2012.
10. Adeola HA, Smith M, Kaestner L, Blackburn JM and Zerbini LF: Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort. Oncotarget 7: 13945-13964, 2016.
11. Li M, Qian Z, Ma X, Lin X, You Y, Li Y, Chen T and Jiang H: MiR-628-5p decreases the tumorigenicity of epithelial ovarian cancer cells by targeting at FGFR2. Biochem Biophys Res Commun 495: 2085-2091, 2018.
12. Schwartfeger KL: Fibroblast growth factors in development and cancer: Insights from the mammary and prostate glands. Curr Drug Targets 10: 632-644, 2009.
13. BERNARD CH, Ebot EM, Wilson KM and Mucci L: The epidemiology of prostate cancer. Cold Spring Harb Perspect Med 8: pii: a030361, 2018.
14. Srivastava A, Goldberger H, Ditmichev A, Marian C, Soldin O, Li X, Collins SP, Suy S and Kumar D: Circulatory miR-628-5p is downregulated in prostate cancer patients. Tumour Biol 35: 4867-4872, 2014.
15.Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta CT) method. Methods 25: 402-408, 2001.
16. Parraou AJ and Samaranayake P: miR-500-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukaemia. Leuk Res 36: 334-341, 2012.
17. Bryzgunova OE, Konoshenko MY and Laktionov PP: MicroRNA-guided gene expression in prostate cancer: Literature and database overview. J Gene Med 20: e3016, 2018.
18. Mirzaei H, Masoudifar A, Sahelkar A, Zare N, Sadri Nahand J, Rashidi B, Mehrabian E, Mohammadi M, Mirzaei HR and Jaafari MR: MicroRNA: A novel target of curcumin in cancer therapy. J Cell Physiol 233: 3004-3015, 2018.
19. Sun H, Ying H, Datwen C, Bing Y, Xiangbing M, Ping Z, Jie Y, Zhiqing H and Junqiu L: miR-628, a microRNA that is induced by Toll-like receptor stimulation, regulates porcine innate immune responses. Sci Rep 5: 12226, 2015.
20. Yu Y, Li X, Liu L, Chai J, Haijun Z, Chai W, Yin H, Ma L, Duan H and Xiao M: miR-628 promotes burn-induced skeletal muscle atrophy via targeting IRS1. Int J Biol Sci 12: 1213-1224, 2016.
21. Chen H, Ji X, She F, Gao Y and Tang P: miR-628-3p regulates osteoblast differentiation by targeting RUNX2. Possible role in atrophic non-union. Int J Mol Med 39: 279-286, 2017.
22. Rosini A, Bonaccorsi L, Baldi E, Chiassertini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Iozzo RV, Garaci E, et al: Androgen receptor expression induces FGF2, FGF-binding protein production and FGFR2 release in prostate carcinoma cells: Role of FGFR2 in growth, survival and androgen receptor down-modulation. Prostate 53: 310-321, 2002.
23. Giri D, Ropiquet F and Ittmann M: Alterations in expression of basic fibroblast growth factor (FGF2) and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 5: 1063-1071, 1999.
24. Ropiquet F, Huguenin S, Villette JM, Ronflé V, Le Brun G, Maitland NJ, Cussenot O, Fiet J and Berthon P: FGF7/KGF triggers cell transformation and invasion on immortalised human prostatic epithelial PNT1A cells. Int J Cancer 82: 237-243, 1999.

25. Katoh Y and Katoh M: FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). Int J Mol Med 23: 307-311, 2009.

26. Carstens RP, Eaton JV, Krigman HR, Walther PJ and Garcia-Blanco MA: Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 15: 3059-3065, 1997.

27. Muh SJ, Hovhannisyan RH and Carstens RP: A Non-sequence-specific double-stranded RNA structural element regulates splicing of two mutually exclusive exons of fibroblast growth factor receptor 2 (FGFR2). J Biol Chem 277: 50143-50154, 2002.

28. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O and Berthon P: Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 52: 245-252, 2002.

29. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T and Visakorpi T: MicroRNA in prostate, bladder, and kidney cancer: A systematic review. Eur Urol 59: 671-681, 2011.

30. Curtin CM, Castaño IM and O’Brien FJ: Scaffold-based microRNA therapies in regenerative medicine and cancer. Adv Healthc Mater 7, 2018.

31. Hosseinahli N, Aghapour M, Duijf PHG and Baradaran B: Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol 233: 5574-5588, 2018.

32. Weidle UH, Birzele F, Kollmorgen G and Nopora A: Potential microRNA-related targets for therapeutic intervention with ovarian cancer metastasis. Cancer Genomics Proteomics 15: 1-15, 2018.